Related Experiment Videos
Pyridazine based inhibitors of p38 MAPK
Charles J McIntyre1, Gerald S Ponticello, Nigel J Liverton
1Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. mcintyre@merck.com
Bioorganic & Medicinal Chemistry Letters
|February 15, 2002
Abstract:
Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38MAPK. The most active isomers were those possessing an aryl group alpha and a heteroaryl group beta relative to the nitrogen atom in the 2-position of the central pyridazine. Additionally, substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC50 1-20 nM) in vitro activity.